New Delhi, Oct. 14 -- Johnson & Johnson (J&J), the global healthcare industry bellwether, announced on Tuesday its plan to separate its orthopaedics division from the main company within the next 18 to 24 months. This major organisational shift was revealed as the pharmaceutical and medical technology firm reported third quarter results that surpassed Wall Street expectations.

The orthopaedics business, which focuses on products such as hip and knee replacements and spinal equipment, is currently known as DePuy Synthes and generated approximately $9.2 billion in sales in 2024.

J&J Chief Financial Officer Joseph Wolk explained that whilst DePuy Synthes is "still a great business," it is not as fast-growing or as profitable as J&J's other...